Short answer
Vanda Pharmaceuticals Inc. (VNDA) filed an 8-K current report with the SEC on March 10, 2026 reporting Item 7.01 (Regulation FD Disclosure). Vanda Pharmaceuticals filed a Reg FD disclosure (Item 7.01), signaling a potentially market-moving communication to investors.
Vanda Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Vanda Pharmaceuticals filed a Reg FD disclosure (Item 7.01), signaling a potentially market-moving communication to investors
- No substantive disclosure content included in this section: material information likely contained in an accompanying exhibit
- Signed by SVP & General Counsel Timothy Williams on March 10, 2026; review attached exhibit(s) for the actual disclosed information
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vanda Pharmaceuticals Inc. 8-K filings
Get the next VNDA 8-K as it lands
Follow VNDA for push alerts, or ask the research agent what this filing means.